Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Egetis Therapeutics

5.37 SEK

+0.19 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.19 %
+8.27 %
+0.56 %
+4.27 %
+7.94 %
+31.94 %
+4.27 %
-6.80 %
-61.19 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.28B SEK
Turnover
2.15M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29/4
2026

Interim report Q1'26

6/5
2026

General meeting '26

21/8
2026

Interim report Q2'26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release12 hours ago

KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)

Egetis Therapeutics
Regulatory press release12 hours ago

NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Egetis Therapeutics
Press release3/9/2026, 6:00 AM

Egetis erhåller Notice of Allowance avseende MCT8-brist sammansättningspatent i USA

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/9/2026, 6:00 AM

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Egetis Therapeutics
Press release3/5/2026, 9:56 AM

Redeye: Egetis Therapeutics (Q4 review): US approval on the horizon

Egetis Therapeutics
Press release3/2/2026, 4:10 PM

Egetis Therapeutics lanserar informationswebbplatser om MCT8‑brist för läkare och vårdgivare

Egetis Therapeutics
Press release3/2/2026, 4:10 PM

Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q4'25
Webcast2/26/2026, 9:00 AM

Egetis Therapeutics, Audiocast, Q4'25

Egetis Therapeutics
Regulatory press release2/26/2026, 6:00 AM

Bokslutskommuniké januari-december 2025

Egetis Therapeutics
Regulatory press release2/26/2026, 6:00 AM

Year-End Report January-December 2025

Egetis Therapeutics
Press release2/24/2026, 10:00 AM

Egetis Therapeutics presenterar vid kommande investerarevent

Egetis Therapeutics
Press release2/24/2026, 10:00 AM

Egetis Therapeutics to Present at Upcoming Investor Events

Egetis Therapeutics
Press release2/19/2026, 9:30 AM

Inbjudan till presentation av Egetis kvartalsrapport Q4 och bokslutskommuniké 2025 den 26 februari 2026

Egetis Therapeutics
Press release2/19/2026, 9:30 AM

Invitation to presentation of Egetis’ fourth quarter and year-end 2025 report on February 26, 2026

Egetis Therapeutics
Press release2/16/2026, 6:00 AM

Egetis uppdaterar om framsteg med utvecklingen av Emcitate® (tiratricol) för MCT8-brist i Japan

Egetis Therapeutics
Press release2/16/2026, 6:00 AM

Egetis provides update on progress with the development of Emcitate® (tiratricol) for MCT8 deficiency in Japan

Egetis Therapeutics
Press release2/4/2026, 2:25 PM

FDAs program för prioriterad granskning av sällsynta pediatriska sjukdomar förlängt till 2029

Egetis Therapeutics
Press release2/4/2026, 2:25 PM

FDA's rare pediatric disease priority review program extended until 2029

Egetis Therapeutics
Regulatory press release1/29/2026, 6:00 AM

Egetis slutför rullande ansökan om marknadsgodkännande (NDA) i USA för Emcitate® (tiratricol) för behandling av MCT8-brist

Egetis Therapeutics
Regulatory press release1/29/2026, 6:00 AM

Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency

Egetis Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.